Liraglutide attenuates gefitinib-induced cardiotoxicity and promotes cardioprotection through the regulation of MAPK/NF-κB signaling pathways

Gefitinib is an effective treatment for patients with locally advanced non-small cell lung cancer. However, it is associated with cardiotoxicity that can limit its clinical use. Liraglutide, a glucagon-like peptide 1 receptor agonist, showed potent cardioprotective effects with the mechanism is yet...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Saudi Pharm J
Hauptverfasser: AlAsmari, Abdullah F., Ali, Nemat, AlAsmari, Fawaz, AlAnazi, Wael A., AlShammari, Musaad A., Al-Harbi, Naif O., Alhoshani, Ali, As Sobeai, Homood M., AlSwayyed, Mohammed, AlAnazi, Mohammed M., AlGhamdi, Nader S.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Elsevier 2020
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7132601/
https://ncbi.nlm.nih.gov/pubmed/32273812
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jsps.2020.03.002
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge